December 9, 2014
Eisai said on December 8 that its antiepileptic drug Fycompa (perampanel) as an adjunctive therapy significantly lowered the frequency of primary generalized tonic-clonic (PGTC) seizures, excluding secondary generalized seizures, in a placebo-controlled PIII study, dubbed Study 332. The double-blind, randomized,...read more